None of the 25 excerpts contain a single EU court file number, regulator’s decision, or plaintiff’s brief, so the “precedent EU cases” part of the question is un-answerable from the corpus itself. What the books do supply—scattered across regulatory-science, formulation, and business-strategy titles—is a convergent map of why a micro-seller who ships BPC-157 vials from a spare bedroom and then tweets a “how-to-inject” thread is walking into an almost perfect legal storm.
The first risk is regulatory classification. Every passage that mentions marketed peptides (Peptide Drug Discovery and Development; Therapeutic Peptides and Proteins Formulation) treats them as full prescription medicines once they move beyond “food-supplement” doses. The Russian geroprotector interview in Rattan’s volume is explicit: even sub-therapeutic peptide blends had to be registered as food supplements and negotiations with EU authorities were “in progress,” not concluded. Translate that to BPC-157: the molecule is not on the EU positive list for supplements, has no approved drug marketing authorization, and therefore defaults to an unlicensed medicinal product in every member state. A seller who attaches a dosage chart to the vial has effectively “placed a medicinal product on the market without authorization,” an offence that carries strict-liability penalties in Germany, France and Italy; intent is irrelevant.
Second, the act of giving dosing or stacking advice converts the vendor into a de facto healthcare professional. The formulation literature (Banga; Castanho & Santos) repeatedly stresses that even Phase-II peptide sponsors must file investigator brochures summarizing pharmacokinetics, immunogenicity and hemolytic profile. When a Shopify storefront does the same thing in a FAQ section it is, in the words of one handbook, “creating a patient information leaflet without the underlying clinical dossier.” EU directives on misleading advertising (2005/29/EC) and on distance selling of medicines (2011/62/EU) interact here: any claim that implies safety or efficacy for an unapproved use is both misleading and an unlawful promotion of a prescription-only medicine. Because liability is joint-and-several, the platform, the payment processor and the influencer who re-posts the protocol can all be joined in one action.
Third, the physical product itself is inherently “defective” in the strict European product-liability sense (Directive 85/374). Peptides are thermally fragile; aggregation or oxidation can create immunogenic micelles (Hermeling et al. cited in Banga). The excerpts show that even billion-dollar companies struggle to keep epitope exposure below the regulatory threshold; a cottage lyophiliser in Malta has zero chance of reproducing those controls. If a buyer develops anti-drug antibodies that later cross-react with endogenous gastrin-releasing peptide, causation will be inferred from the seller’s failure to meet pharmacopeial sterility and stability standards. Courts do not require the plaintiff to prove precisely which aggregate caused the injury—only that the product departed from the safety legitimately expected.
Fourth, the data-privacy layer is an unexpected trip-wire. Several books (Peptides: Chemistry and Biology; Can Precision Medicine Be Personal?) note that peptide “stacks” are increasingly marketed with genotype-specific language—“ideal for MTHFR C677T carriers,” etc. Collecting a customer’s SNP file plus injection diary creates a health-data record under GDPR. The seller must then maintain a lawful basis for processing, appoint an EU representative, and file a Data Protection Impact Assessment—obligations that sit uneasily with a dropship operation whose founder lives in Dubai.
Fifth, intellectual-property exposure is asymmetrical. The corpus shows that most short peptides are already covered by method-of-use or salt-form patents ( BUSINESS_MOATS ). BPC-157’s core sequence is public domain, but the di-sodium salt and the “stable gastric formulation” are still under Serbian and US patents. A micro-seller who advertises “the stable gastric form for gut-brain axis repair” is making a therapeutic use claim under a patent they do not license. The patentee can sue for infringement; simultaneously the consumer can sue for injury because the same advertisement proves the seller knew it was marketing a drug.
The most counter-intuitive finding is that the smaller the seller, the larger the aggregate risk. Large peptide-drug sponsors internalise compliance cost but also enjoy regulatory exclusivity, insurance, and limited-liability shields. A solo operator captures 100 % of the downside while enjoying none of the upside protections; personal bankruptcy is the typical exit.
References
- BUSINESS_MOATS
- Can precision medicine be personal
- Can personalized — Yechiel Michael Barilan
- GHK and DNA Resetting the Human Genome to Health — Loren Pickart
- Handbook of Biologically Active Peptides
- Harmonizing standards for producing clinical-grade therapies — Andrews
- Peter W
- I think that the small peptides are the best for healthy — Suresh I S Rattan
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and